Ultime notizie per C4 Therapeutics (NASDAQ:CCCC) Azioni

C4 Therapeutics

C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.

C4 Therapeutics Inc

C4 Therapeutics ( ($CCCC) ) has shared an update. C4 Therapeutics has appointed Paige Mahaney, Ph.D., as the new Chief Scientific Officer, succeedi...

C4 Therapeutics Appoints New Chief Scientific Officer

C4 Therapeutics GAAP EPS of -$0.35 beats by $0.05, revenue of $15.36M beats by $10.76M

17:30 EDT C4 Therapeutics (CCCC) files $400M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving br...

C4 Therapeutics files $400M mixed securities shelf

17:29 EDT C4 Therapeutics (CCCC) files to sell 4.87M shares of common stock for holders Published first on TheFly – the ultimate source for real-ti...

C4 Therapeutics files to sell 4.87M shares of common stock for holders

C4 Therapeutics, Inc. ( ($CCCC) ) has released its Q3 earnings. Here is a breakdown of the information C4 Therapeutics, Inc. presented to its inves...

C4 Therapeutics Advances in Protein Degradation Therapy

C4 Therapeutics (CCCC) announced its partner Betta Pharmaceuticals has dosed the first patient in the Phase 1 clinical trial of CFT8919, an orally ...

C4 Therapeutics announces first patient dosed in CFT8919 clinical trial

C4 Therapeutics: Holding Fast To A Generous Valuation Heading Into An Important ASH Readout

Stephens initiated coverage of C4 Therapeutics (CCCC) with an Equal Weight rating and $4 price target The firm is adding to its Biotechnology resea...

C4 Therapeutics initiated with an Equal Weight at Stephens

C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director. Published f...

C4 Therapeutics appoints Hoerter to board of directors

The latest update is out from C4 Therapeutics ( ($CCCC) ). C4 Therapeutics has appointed Steve Hoerter to its Board of Directors, highlighting the ...

C4 Therapeutics Appoints Steve Hoerter to Board

CCCC

Markets

Press Releases

C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

News

C4 Therapeutics Announces Presentations and Participation in 7th Annual Targeted Protein Degradation & Induced Proximity Summit

Management

C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Health Care

General

Earnings

C4 Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Seaport Therapeutics Names Lauren White as Chief Financial Officer

PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

C4 Therapeutics to Present Data from the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting

C4 Therapeutics Announces First Patient Dosed in CFT8919 Clinical Trial

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors

ABBV

IMGN

PRTC

Abeona Therapeutics

Absci

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics

Anika Therapeutics

Artiva Biotherapeutics, Inc. - Common Stock

Artiva Biotherapeutics

aTyr Pharma

Perspective Therapeutics, Inc. Common Stock

Perspective Therapeutics

COMPASS Pathways Plc - American Depository Shares

Compass Pathways

Eledon Pharmaceuticals, Inc. - Common Stock

Eledon Pharma

Fate Therapeutics

Immutep Limited - American Depositary Shares

Immutep

ITeos Therapeutics

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics

Lexicon Pharmaceuticals, Inc. - Common Stock

Lexicon Pharmaceuticals

Lyell Immunopharma

Mersana Therapeutics, Inc. - Common Stock

Mersana Therapeutics

Ocugen

Precigen

Q32 Bio

AVITA Medical

Rezolute

Tenaya Therapeutics

Valneva

Vanda Pharmaceuticals Inc. - Common Stock

Vanda Pharma

Voyager Therapeutics, Inc. - Common Stock

Comments

C4 Therapeutics

Notizie

Ultime notizie per C4 Therapeutics (NASDAQ:CCCC) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO